OUR TECHNOLOGY

At Genomic Medicine UK, we provide a comprehensive panel of genomic tests and services. Our highly qualified consultant medical doctors carry out our extensive tests and services using state-of-the-art advanced technologies such as next-generation DNA sequencing, DNA chip microarray and DNA genotyping technologies. You can find below a list of the genomic tests and services that we provide at Genomic Medicine UK:

A

Genomic tests that can be carried out on a DNA sample collected by buccal swabs or a saliva sample in your clinic, which can be sent by post to Genomic Medicine UK:

1

Personalised medical treatments for diseases (500+ panels)
Innovative DNA testing to explore how your patient’s genes can affect and modulate her/his response to prescribed drugs. This type of testing is vital to help you to prescribe effective, safe medications and adjust your prescription doses in a personalised approach that accommodates your patient’s genetic makeup.

2

Genomic risk assessment for common diseases (50+ panels)
Advanced DNA analysis to find out whether your patient’s genetic background may increase her/his risk of developing certain types of illnesses such as cardiovascular disease, hypercholesterolaemia, hyperlipidaemia, ischaemic heart attack, ischaemic stroke and Alzheimer’s disease.

3

Genomic risk assessment for hereditary malignancies (25+ panels covers almost all types of cancers)
Modern DNA analysis using the cutting edge technology of next-generation DNA sequencing to find germline mutations that may increase your patient’s risk of developing a specific type of malignancies.

4

Genomic cancer prevention tests (5 panels)
Modern DNA analysis using the cutting edge technology of next-generation DNA sequencing to find germline mutations that may increase your patient’s risk of developing a specific type of malignancies.

5

Precision oncology pharmacogenomics (25+ panels)
Cutting-edge genomic tests to study of the effect of inherited genomic variations within the patient’s germline genome on cancer chemotherapy response and examine the speed of metabolising any chemotherapy drug candidate by the cytochrome enzymatic system in the patient’s body, which could be either normal, slow, fast or no metabolism of this drug. It also assesses the inherited genomic risk for developing side effects if being treated with this chosen chemotherapy drug.

6

Nutritional and weight control medicine genomic tests (3 panels)
Cutting-edge genomic tests to study of the effect of inherited genomic variations within the patient’s germline genome on cancer chemotherapy response and examine the speed of metabolising any chemotherapy drug candidate by the cytochrome enzymatic system in the patient’s body, which could be either normal, slow, fast or no metabolism of this drug. It also assesses the inherited genomic risk for developing side effects if being treated with this chosen chemotherapy drug.

7

Personalised medical treatments with specific medicines (2300+ panels)
A group of groundbreaking pharmacogenomic DNA tests designed to explore how your patient’s genes can affect and modulate her/his response to a specific prescribed drug. The response and speed of metabolism of any given prescribed medication are not at the same level between any two individuals. This type of testing is vital to help you to prescribe effective, safe drugs and adjust your prescribed doses in a personalised approach that is tailored according to your patient’s genetic makeup. We can provide personalised pharmacogenomic assessment for the 2329 individual medicines, which comprise the majority of the prescribed medicaments by the family doctors and specialists in the United Kingdom and worldwide.

b

Genomic tests that can be carried out on a formalin fixed paraffin embedded (FPPE) tissue/biopsy and buccal swabs samples which can be sent by post:

1

Targeted cancer therapy and oncology pharmacogenomics
A novel combined genomic test that combines the power of finding out the genomic somatic alterations in the genes that drive tumorigenesis within the DNA of the tumorous cells by next-generation sequencing to have a greater insight into drug sensitivity and/or resistance as well as disease prognosis of this tumour, thus enabling personalised care of each cancer patient. Moreover, this genomic test incorporates the pharmacogenomic analysis of the patient’s inherited variations within her/his germline genome to assess the speed of metabolising any chemotherapy drug candidate by the cytochrome enzymatic system in the patient’s body, which could be either normal, slow, fast or no metabolism of this drug. It also assesses the inherited genomic risk for developing side effects for a specific chemotherapy drug.

c

Genomic tests that can be carried out on a blood sample you can draw in your clinic and post it back with the Royal Mail to Genomic Medicine UK:

1

Targeted cancer therapy circulating tumour DNA (ctDNA) liquid biopsy
A sophisticated and non-invasive genomic test that analyses the majority of solid tumours for targeted therapy selection, treatment monitoring and management solutions using tumour-derived fragmented DNA shed from a tumour into the bloodstream. It is a comprehensive clinical liquid biopsy test to detect somatic alterations (SNVs, indels, CNVs, and fusions).

d

Genomic tests that require collecting a blood sample at Genomic Medicine UK clinic in central London:

1

Cancer treatment and remission circulating tumour cells (CTCs)monitor (liquid biopsy)
A non-invasive, highly accurate, and affordable blood test specifically designed for better management of cancer patients. This advanced genomic test is designed for seventeen different cancer types of epithelial origin and can be utilised as an ancillary tool for recurrence and response to treatment monitoring without subjecting the patient to invasive procedures and harmful radiation. This test is conventionally named as a “liquid biopsy” and can be used at any time during a patient’s course of the disease.

2

Colorectal cancer circulating tumour cell (CTC) screening test
A highly sensitive circulating tumour cell (CTC) genomic test specifically designed for early detection of colorectal cancer and colorectal precancerous lesions at very early stages of the tumourigenesis process.

3

Prostate cancer circulating tumour cell (CTC) screening test
A highly sensitive and imprecise circulating tumour cell (CTC) genomic test specifically designed for early detection of prostate cancer at very early stages of the tumourigenesis process to clarify whether a patient can avoid unnecessary diagnostic biopsy following inconclusive results from PSA testing.

READ MORE

& many more genomic tests…

X